A 10 mg retatrutide vial with 1 mL BAC water gives 10 mg/mL (a 4 mg dose = 40 units on a U-100 syringe)
Stakeholders Interviewed Primary interviews for this study involved: Manufacturers and suppliers in the market value chain Distributors, channel partners, and integrators End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market) Industry experts, technology specialists, consultants, and regulatory professionals Senior executives (CEOs, CTOs, VPs, Directors) and product managers Interview Process Interviews were conducted via: Structured and semi-structured questionnaires Telephonic and video interactions Email correspondences Expert consultation sessions Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation
Blood levels of CRP above 3 mg/L are suggested to be predictive of adverse cardiovascular outcome one year later 48
Originally approved by the FDA for the treatment of adult obesity in 2014, the drug received authorisation in 2020 for obesity in adolescents aged 12-17 years old (Mller, Blher, Tschp, DiMarchi)
